RecruitingPhase 3NCT06126822
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Tropical Medicine, Belgium
- Principal Investigator
- Wim Adriaensen, Prof.Institute of Tropical Medicine
- Intervention
- Zabdeno® booster(drug)
- Enrollment
- 624 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2025 – 2026
Study locations (2)
- Institut National de Recherche Biomédicale (INRB), Goma, Democratic Republic of the Congo
- Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
Collaborators
Institut National pour la Recherche Biomedicale (INRB)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06126822 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University